
    
      Study duration for one patient will include a period for inclusion (screening period) of up
      to 4 weeks, a treatment period of at least 4 weeks, and a end-of-study visit at 30 days
      following the last administration of study drug. The patient may continue treatment until
      disease progression, unacceptable toxicity or willingness to stop, followed by a minimum of
      30-days follow-up.
    
  